Latest Regulatory Milestones News

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

RareX Limited has achieved a major regulatory milestone with the granting of a Mining Lease for its Cummins Range Project in Western Australia, significantly reducing development risk and paving the way for focused metallurgical optimisation and mine planning.

Estrella Resources has gained regulatory approval to extract a 30,000-tonne bulk sample of high-grade manganese from its Ira Miri project, marking a pioneering step for Timor-Leste’s mining sector under its modern Mining Code.

Lunnon Metals has secured the last regulatory approval needed to advance its Lady Herial gold project, bringing it closer to production under a key agreement with St Ives Gold Mining.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

Aurum Resources has taken a major step forward at its Boundiali Gold Project in Côte d'Ivoire by lodging three mining licence applications covering over 570 square kilometres, setting the stage for a busy 2026 with extensive drilling and resource updates.

Viridis Mining and Minerals has secured a pivotal US$50 million Letter of Support from Export Finance Australia, finalising the export credit agency-led debt package for its Colossus Rare Earths Project. This milestone positions the project to advance towards full funding and a Final Investment Decision in the second half of 2026.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.